Global Transcriptional Complexity of Estrogen Receptor–Low Positive Breast Cancers in the Prospective Swedish Population–Based SCAN-B Cohort
ER-low/HER2-negative is not a distinct breast cancer molecular biological entity but an integral part of TNBC, deserving similar treatments. Nonetheless, a few borderline cases with moderately active ER signaling can potentially respond to endocrine therapies. Hormone receptor-related signatures and tumor-infiltrating lymphocytes may stratify ER-low/HER2-negative tumors according to the risk of recurrence. The true benefit of endocrine therapies in ER-low breast cancer requires prospective investigation.
Authors
- Siker Kimbung (ORCID: https://orcid.org/0000-0002-7001-8367)
- Johan Vallon‐Christersson (ORCID: https://orcid.org/0000-0002-2195-0385)
- Anna Ehinger (ORCID: https://orcid.org/0000-0001-9225-7396)
- Kadum Muhammad
- Srinivas Veerla (ORCID: https://orcid.org/0000-0001-7328-6239)
- Martin Malmberg (ORCID: https://orcid.org/0000-0002-9500-8982)
- Niklas Loman (ORCID: https://orcid.org/0000-0003-1425-5189)
Institutions
- Malmö University (SE)
- Lund University (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3435
- Citations
- 2
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Vetenskapsrådet